Alexion is expanding its OneSource™ Treatment Support Program to U.S. patients with atypical hemolytic uremic syndrome (aHUS)
now that the FDA has approved Soliris for this use. Since 2007, OneSource has provided personalized, ongoing support for
patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, life-threatening blood disorder. Patients and families in the United States affected by
aHUS can call 1-888-SOLIRIS to speak with an Alexion Nurse Case Manager, who can help answer questions about the OneSource program,
discuss funding options for Soliris, provide education on disease and drug, and provide ongoing treatment support.